WMA
IBRX icon

Wealth Management Associates’s ImmunityBio IBRX Stock Holding History

Wealth Management Associates’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$466K Buy
60,700
+41,700
+219% +$285K 0.16% 124
2025
Q4 		$37.6K Buy
+19,000
New +$43K 0.01% 234

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Wealth Management Associates's IBRX Position: Q1 2026 in Review

Wealth Management Associates increased its ImmunityBio (IBRX) stake by 219% in Q1 2026, buying an estimated $285K and bringing the position to 60,700 shares worth $466K. The position accounts for 0.16% of the portfolio, ranked #124.

Wealth Management Associates first reported a position in IBRX in Q4 2025 and has held it in 2 quarters since. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • Wealth Management Associates held 60,700 shares of ImmunityBio worth $466K as of Q1 2026.
  • Wealth Management Associates bought 41,700 ImmunityBio shares in Q1 2026, an estimated $285K.
  • ImmunityBio made up 0.16% of Wealth Management Associates's portfolio in Q1 2026, its #124 holding.
  • Wealth Management Associates first reported a position in ImmunityBio in Q4 2025 and has held it in 2 quarters since.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Wealth Management Associates's 13F filing for Q1 2026, filed 13 May 2026.